Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Janux Therapeutics Inc
(NQ:
JANX
)
40.17
+2.06 (+5.41%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Janux Therapeutics Inc
< Previous
1
2
3
4
5
Next >
Janux Therapeutics Appoints Winston Kung to Board of Directors
September 22, 2022
From
Janux Therapeutics, Inc.
Via
Business Wire
Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September
August 31, 2022
From
Janux Therapeutics, Inc.
Via
Business Wire
Advance Auto Parts, Nordstrom And Other Big Stocks Recording Losses On Wednesday
August 25, 2022
U.S. stocks closed higher with the Nasdaq Composite gaining 50 points on Wednesday. Here is the list of some big stocks moving lower in the previous session.
Via
Benzinga
Why Minerva Neurosciences Shares Traded Higher By Over 66%; Here Are 78 Biggest Movers From Yesterday
August 25, 2022
Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) shares gained 66.5% to close at $7.51 after Point72 Asset Management reported an 8.8% passive stake in the company.
Via
Benzinga
Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
August 09, 2022
From
Janux Therapeutics, Inc.
Via
Business Wire
Zendesk, Quotient, + 40 Stocks Moving In Friday's Mid-Day Session
June 24, 2022
Gainers USA Truck, Inc. (NASDAQ: USAK) shares jumped 111% to $30.76. DB Schenker and USA Truck announced plans to combine and create premier North American transportation solutions provider.
Via
Benzinga
Looking Into Janux Therapeutics's Return On Capital Employed
June 13, 2022
According to Benzinga Pro data, during Q1, Janux Therapeutics (NASDAQ:JANX) posted sales of $1.59 million. Earnings were up 0.04%, but Janux Therapeutics still reported an overall loss of $13.41...
Via
Benzinga
Janux Therapeutics to Present at 2022 Jefferies Global Healthcare Conference
June 02, 2022
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Announces FDA Clearance of Investigational New Drug Application for JANX007, a PSMA-TRACTr for Metastatic Castration-Resistant Prostate Cancer
May 31, 2022
From
Janux Therapeutics, Inc.
Via
Business Wire
Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
May 10, 2022
From
Janux Therapeutics, Inc.
Via
Business Wire
Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr
April 26, 2022
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics's Return On Capital Employed Overview
March 21, 2022
Janux Therapeutics (NASDAQ:JANX) brought in sales totaling $1.62 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 24.61%, resulting in a...
Via
Benzinga
Janux Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
March 18, 2022
From
Janux Therapeutics, Inc.
Via
Business Wire
Janux Therapeutics to Present Virtually at the H.C. Wainwright BioConnect Conference
January 05, 2022
From
Janux Therapeutics, Inc.
Via
Business Wire
Janux Therapeutics Reports Business Highlights and Third Quarter 2021 Financial Results
November 09, 2021
From
Janux Therapeutics, Inc.
Via
Business Wire
Janux Therapeutics to Present Virtually at Upcoming Investor Conferences
November 08, 2021
From
Janux Therapeutics, Inc.
Via
Business Wire
50 Biggest Movers From Yesterday
September 28, 2021
Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares surged 50% to close at $3.60 on Monday after the company said its subsidiary, Skypersonic, Inc, won a five-year contract from...
Via
Benzinga
48 Biggest Movers From Friday
September 20, 2021
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by...
Via
Benzinga
Janux Therapeutics Appoints Ron Barrett, Ph.D., and Alana McNulty to Board of Directors
September 09, 2021
From
Janux Therapeutics, Inc.
Via
Business Wire
Janux Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investor Conference
September 07, 2021
From
Janux Therapeutics, Inc.
Via
Business Wire
Janux Therapeutics Appoints Shahram Salek-Ardakani, Ph.D., Chief Scientific Officer
July 19, 2021
From
Janux Therapeutics
Via
Business Wire
84 Biggest Movers From Friday
August 09, 2021
Gainers Sphere 3D Corp. (NASDAQ: ANY) shares surged 41.3% to close at $4.86 on Friday after the company inked an agreement with turnkey mining solutions provider Hertford...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2021
July 06, 2021
Upgrades According to Citigroup, the prior rating for ORIC Pharmaceuticals Inc (NASDAQ:
Via
Benzinga
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision, Conference Presentations In A Light Week
July 03, 2021
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
June 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15) Apellis Pharmaceuticals,...
Via
Benzinga
Exposures
COVID-19
Product Safety
Janux Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 15, 2021
From
Janux Therapeutics, Inc.
Via
Business Wire
The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda
June 15, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 14) Alkermes plc (NASDAQ: ALKS...
Via
Benzinga
60 Biggest Movers From Yesterday
June 15, 2021
Gainers RAPT Therapeutics, Inc. (NASDAQ: RAPT) shares jumped 115.5% to settle at $40.02 on Monday as the company announced topline results from its Phase 1b trial of RPT193 as...
Via
Benzinga
Opening Day: Monday.com, Marqeta Jump In Market Debuts
June 13, 2021
Monday.com jumped in its U.S. debut after the workplace management software maker raised $574M in its initial public offering. Meanwhile, Marqeta's shares also soared on their first day of trading on...
Via
Talk Markets
64 Biggest Movers From Friday
June 14, 2021
Gainers Kanzhun Limited (NASDAQ: BZ) shares climbed 95.8% to close at $37.20 on Friday after the company priced its IPO at $19 per share. Novan, Inc. (NASDAQ: NOVN) shares gained...
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.